Charles F. Wagner
Executive VP, COO & CFOMr. Charles F. Wagner, Jr. also known as Charlie, is President of Crinetics Pharmaceuticals, Inc. from September 1, 2026. Mr. Wagner serves as Independent Director of The TJX Companies, Inc. since September 20, 2023. He serves as Executive VP and Chief Financial Officer at Vertex Pharmaceuticals Incorporated since April 10, 2019 and also serves as its Chief Operating Officer since July 01, 2025. He joined Vertex in 2019. He serves as Treasurer and Director of Semma Therapeutics, Inc. He served as a Director of Good Start Genetics, Inc. since April 2014 until August 2017. He served as Chief Financial Officer of Ortho-Clinical Diagnostics, Inc. since June 2015 until March 2019. He served as Chief Financial Officer at Ortho-Clinical Diagnostics N.V. Mr. Wagner has a consistent record of creating value by improving the operational and financial health of complex global organizations across multiple industries. Prior to joining OCD in June 2015, Mr. Wagner served as Chief Financial Officer and Executive Vice President of Bruker Corporation from July 2012 to June 12, 2015. Mr. Wagner served as the Chief Financial Officer and Executive Vice President of Finance & Administration of IONA Technologies Limited. He served as the Chief Financial Officer and Executive Vice President of Finance & Administration at Progress Software Corp. from November 15, 2010 to March 22, 2012. Prior to joining Progress Software, Mr. Wagner served as the Chief Financial Officer and Corporate Vice President of EMD Millipore Corporation., from August 15, 2007 to July 2010. He served as the Vice President of Strategic Planning and Business Development of EMD Millipore Corporation, from March 1, 2003 to 2007 and served as its Vice President since March 2003. Mr. Wagner served as Vice President of Strategy and Corporate Development at Millipore from 2003 to 2007. He joined EMD Millipore Corporation., in December 2002 as Director of Strategic Planning and Business Development. Mr. Wagner served as a Manager of Bain & Company from 2001 to 2002 and Consultant in the corporate strategy and private equity practices from 1997 to 2002. He served as the Manager of Corporate Accounting Analysis at Millipore from 1995 to 1996 and held positions at Coopers & Lybrand LLP from 1990 to 1995. He began his career in public accounting at Coopers & Lybrand. He worked in Corporate Finance for Millipore. Mr. Wagner served as an Independent Director at Bruker Energy & Supercon Technologies, Inc. since June 24, 2010. He served as a Director of Bruker Corporation from August 3, 2010 to June 04, 2012. He practiced public accounting from 1990 to 1995 at Coopers & Lybrand LLP, where he earned his CPA. He holds a Bachelor of Science degree in Accounting, summa cum laude from Boston College, Wallace E. Carroll School of Management. From 1996 to 1998, Mr. Wagner attended Harvard University Graduate School of Business Administration, where he received his MBA.
Positions
- Company NameVertex Pharmaceuticals IncorporatedStock CodeVRTXPositionExecutive VP, COO & CFOColleagues
- JMJeffrey Marc LeidenExecutive Chairman
- RKReshma KewalramaniCEO, President & Director
- AKAmit K. SachdevExecutive VP & Chief Patient and External Affairs Officer
- OTOurania TatsisExecutive VP & Chief Product Affairs Officer
- BIBruce I. SachsLead Independent Director
- LALloyd A. CarneyIndependent Director
- MLMichel LagardeIndependent Director
